Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

Background & Aims Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH‐2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha‐fetoprotein (AFP) ≥400 ng/mL showed an...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2020-08, Vol.40 (8), p.2008-2020
Main Authors: Kudo, Masatoshi, Galle, Peter R., Llovet, Josep M., Finn, Richard S., Vogel, Arndt, Motomura, Kenta, Assenat, Eric, Merle, Philippe, Brandi, Giovanni, Daniele, Bruno, Okusaka, Takuji, Tomášek, Jiří, Borg, Christophe, Dadduzio, Vincenzo, Morimoto, Manabu, Pracht, Marc, Jen, Min‐Hua, Drove Ubreva, Nora, Widau, Ryan C., Shinozaki, Kenta, Yoshikawa, Reigetsu, Zhu, Andrew X.
Format: Article
Language:English
Subjects:
Age
Aged
alpha-Fetoproteins
alpha‐fetoprotein (AFP)
Antibodies, Monoclonal, Humanized
Cancer
Carcinoma, Hepatocellular - drug therapy
elderly
Hazard assessment
Hepatitis
Hepatitis C
Hepatocellular carcinoma
Human health and pathology
Humans
Hépatology and Gastroenterology
Life Sciences
Liver cancer
Liver Neoplasms - drug therapy
Older people
Patients
Pharmaceutical sciences
Pharmacology
Ramucirumab
Regression analysis
Safety
Sorafenib
sorafenib intolerance
Subgroups
Survival
Treatment Outcome
VEGFR2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH‐2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha‐fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post‐hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14462